Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Free Report)’s share price dropped 6.8% on Friday . Weiss Ratings restated a “sell (d-)” rating on shares of Relmada Therapeutics in a research report on Thursday, June 18th. Get Relmada Therapeutics alerts:Check Out Our Latest Report on Relmada TherapeuticsRelmada Therapeutics Stock Down 8.0%The stock has a market capitalization of $518.16 million, a price-to-earnings ratio of -5.49 and a beta of 0.46. As a group, analysts forecast that Relmada Therapeutics, Inc. will post -0.82 EPS for the current fiscal year. See AlsoReceive News & Ratings for Relmada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relmada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.